{'fraction_non_alphanumeric': 0.032670454545454544, 'fraction_numerical': 0.002840909090909091, 'mean_word_length': 5.911764705882353, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Estimating the cost‐effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b

Standard of care for chronic hepatitis C in Japan is currently a pegylated interferon (IFN)‐α + ribavirin (PR)‐based regimen, notably associated with efficacy and tolerability issues. The advent of novel direct‐acting antivirals (DAA) has provided more efficacious and better tolerated treatments. This study investigated the cost‐effectiveness of the daclatasvir + asunaprevir (DCV + ASV) DAA regimen in patients infected with hepatitis C virus (HCV) genotype 1b who had previously not responded to or were ineligible for IFN‐containing regimens.